American Journal of Clinical Dermatology

, Volume 11, Issue 4, pp 233–246

Primary and Metastatic Malignant Tumors of the Scalp

An Update
  • Heather M. Richmond
  • Madeleine Duvic
  • Deborah F. MacFarlane
Review Article Primary and Metastatic Malignant Scalp Tumors


In recent years there have been a number of interesting advances in several topics relating to the diagnosis and treatment of cutaneous lesions with particular applicability to primary and metastatic malignancies of the scalp. In this article we provide a general update of advances in this field, and cover the more salient points relating to a variety of malignant tumors that have been reported to appear on the scalp as primary or metastatic lesions.

A search and review of the literature on PubMed was made to identify and discuss relevant points relating to diagnosis and treatment of primary and metastatic tumors of the scalp.

We describe the anatomy of the scalp, epidemiology of scalp tumors, theories of field cancerization and field therapy, photodynamic therapy, excisional surgical techniques and reconstruction, lymphoscintigraphy, chemoprevention, as well as details relating to atypical fibroxanthoma, Brooke-Spiegler syndrome, nevus sebaceus, cutaneous lymphoma, and metastatic disease.

There is a very broad differential diagnosis for scalp nodules, which includes many different benign and malignant diseases, and treatment should be tailored accordingly. Given the potential for poor prognosis with some of the more aggressive malignancies that can be found in this anatomic area, the importance of a thorough physical examination cannot be emphasized enough, and early detection is critical to provide patients with the best chance for a favorable outcome.


  1. 1.
    Carlson J, Scott D, Wharton J, et al. Incidental histopathologic patterns: possible evidence of ‘field cancerization’ surrounding skin tumors. Am J Dermatopathol 2001 Oct; 23 (5): 494–6PubMedCrossRefGoogle Scholar
  2. 2.
    Tran H, Chen K, Shumack S. Summary of actinic keratosis studies with imiquimod 5% cream. Br J Dermatol 2003; 149 Suppl. 66: 37–9PubMedCrossRefGoogle Scholar
  3. 3.
    Morton C, Brown SB, Collins S, et al. Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group. Br J Dermatol 2002 Apr; 146 (4): 552–67PubMedCrossRefGoogle Scholar
  4. 4.
    Leibovitch I, Huilgol S, Richards S, et al. Scalp tumors treated with Mohs micrographic surgery: clinical features and surgical outcome. Dermatol Surg 2006; 32: 1369–74PubMedCrossRefGoogle Scholar
  5. 5.
    Wright T, Spencer JM, Flowers FP. Chemoprevention of nonmelanoma skin cancer. J Am Acad Dermatol 2006; 54: 933–46PubMedCrossRefGoogle Scholar
  6. 6.
    Chiu C, Lin CY, Kuo CY, et al. Malignant cutaneous tumors of the scalp: a study of demographic characteristics and histologic distributions of 398 Taiwanese patients. J Am Acad Dermatol 2007; 56: 448–52PubMedCrossRefGoogle Scholar
  7. 7.
    Hayman L, Shukla V, Ly C, et al. Clinical and imaging anatomy of the scalp. J Comput Assist Tomogr 2003 Jun; 27 (3): 454–9PubMedCrossRefGoogle Scholar
  8. 8.
    Minor L, Panje WR. Malignant neoplasms of the scalp: etiology, resection, and reconstruction. Otolaryngol Clin North Am 1993 Apr; 26 (2): 279–93PubMedGoogle Scholar
  9. 9.
    Leedy J, Janis JE, Rohrich RJ. Reconstruction of acquired scalp defects: an algorithmic approach. Plast Reconstr Surg 2005; 116 (4): 54e–72ePubMedCrossRefGoogle Scholar
  10. 10.
    Shah K, Onufer J, MacFarlane DF. Imaging of head and neck skin cancer. In: MacFarlane DF, editor. Skin cancer management: a practical approach. New York: Springer, 2010: 239–58Google Scholar
  11. 11.
    Katz T, Silapunt S, Goldberg LH, et al. Analysis of 197 female scalp tumors treated with Mohs micrographic surgery. J Am Acad Dermatol 2005; 52: 291–4PubMedCrossRefGoogle Scholar
  12. 12.
    Abe S, Yamamoto Y, Uno S, et al. Malignant melanoma arising in a sebaceous nevus of the scalp. Br J Plast Surg 2003; 56: 171–3PubMedCrossRefGoogle Scholar
  13. 13.
    Kohler H, Neves RI, Brechtbuhl ER, et al. Cutaneous angiosarcoma of the head and neck: report of 23 cases from a single institution. Otolaryngol Head Neck Surg 2008 Oct; 139 (4): 519–24PubMedCrossRefGoogle Scholar
  14. 14.
    Roesch-Ely M, Nees M, Karsai S, et al. Proteomic analysis reveals successive aberrations in protein expression from healthy mucosa to invasive head and neck cancer. Oncogene 2007 Jan 4; 26 (1): 54–64PubMedCrossRefGoogle Scholar
  15. 15.
    Stern R, Bolshakov S, Nataraj AJ, et al. p53 mutation in nonmelanoma skin cancers occurring in psoralen ultraviolet A-treated patients: evidence for heterogeneity and field cancerization. J Invest Dermatol 2002; 119: 522–6PubMedCrossRefGoogle Scholar
  16. 16.
    Kanjilal S, Strom SS, Clayman GL, et al. p53 Mutations in nonmelanoma skin cancer of the head and neck: molecular evidence for field cancerization. Cancer Res 1995 Aug; 55 (16): 3604–9PubMedGoogle Scholar
  17. 17.
    Gold M, Nestor MS. Current treatments of actinic keratosis. J Drugs Dermatol 2006; 5 (2 Suppl.): 17–25PubMedGoogle Scholar
  18. 18.
    Duvic M, Ni X, Talpur R, et al. Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application. J Invest Dermatol 2003; 121: 902–9PubMedCrossRefGoogle Scholar
  19. 19.
    Morton C, Horn M, Leman J, et al. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or fluorouracil for treatment of squamous cell carcinoma in situ. Arch Dermatol 2006; 142: 729–35PubMedCrossRefGoogle Scholar
  20. 20.
    Naylor M. Imiquimod and superficial skin cancers. J Drugs Dermatol 2005; 4 (5): 598–606PubMedGoogle Scholar
  21. 21.
    Peris K, Fargnoli MC, Chimenti S. Preliminary observations on the use of topical tazarotene to treat basal-cell carcinoma. N Engl J Med 1999 Dec; 341 (23): 1767–8PubMedCrossRefGoogle Scholar
  22. 22.
    Po-Lin S, Lee K, Herbert J, et al. Topical tazarotene chemoprevention reduces basal cell carcinoma number and size in Ptch1+/- mice exposed to ultraviolet or ionizing radiation. Cancer Res 2004; 64: 4385–9CrossRefGoogle Scholar
  23. 23.
    Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B 1990 Jun; 6 (1-2): 143–8PubMedCrossRefGoogle Scholar
  24. 24.
    Nestor M, Gold MH, Kauvar AN, et al. The use of photodynamic therapy in dermatology: results of a consensus conference. J Drugs Dermatol 2006 Feb; 5 (2): 140–54PubMedGoogle Scholar
  25. 25.
    Kache A, Luderschmidt S, Ring J, et al. Photodynamic therapy induces less pain in patients treated with methyl aminolevulinate compared to aminolevulinic acid. J Drugs Dermatol 2006 Apr; 5 (4): 353–6Google Scholar
  26. 26.
    Brown V, Atkins CL, Ghali L, et al. Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients. Arch Dermatol 2005; 141: 985–93PubMedCrossRefGoogle Scholar
  27. 27.
    Perrett C, McGregor JM, Warwick J, et al. Treatment of post-transplant premalignant skin disease: a randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy. Br J Dermatol 2007; 156: 320–8PubMedCrossRefGoogle Scholar
  28. 28.
    Robak E, Robak T. Skin lesions in chronic lymphocytic leukemia. Leuk Lymphoma 2007 May; 48 (5): 855–65PubMedCrossRefGoogle Scholar
  29. 29.
    Yarosh D, Klein J, O’Connor A, et al. Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: a randomized study. Xeroderma Pigmentosum Study Group. Lancet 2001 Mar; 357 (9260): 926–9Google Scholar
  30. 30.
    Mohs F, Zitelli JA. Microscopically controlled surgery in the treatment of carcinoma of the scalp. Arch Dermatol 1981; 117: 764–9PubMedCrossRefGoogle Scholar
  31. 31.
    Belhocine T, Scott AM, Even-Sapir E, et al. Role of nuclear medicine in the management of cutaneous malignant melanoma. J Nucl Med 2006; 47: 957–67PubMedGoogle Scholar
  32. 32.
    Morton D, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006 Sept; 355 (13): 1307–17PubMedCrossRefGoogle Scholar
  33. 33.
    Chao C, Wong SL, Edwards MJ, et al. Sentinel lymph node biopsy for head and neck melanomas. Ann Surg Oncol 2003 Jan-Feb; 10 (1): 21–6PubMedCrossRefGoogle Scholar
  34. 34.
    Kilpatrick L, Shen P, Stewart JH, et al. Use of sentinel lymph node biopsy for melanoma of the head and neck. Am Surg 2007 Aug; 73 (8): 754–8; discussion 8-9PubMedGoogle Scholar
  35. 35.
    Willis A, Ridge JA. Discordant lymphatic drainage patterns revealed by serial lymphoscintigraphy in cutaneous head and neck malignancies. Head Neck 2007; 29: 979–85PubMedCrossRefGoogle Scholar
  36. 36.
    Seavolt M, McCall M. A typical fibroxanthoma: review of the literature and summary of 13 patients treated with Mohs micrographic surgery. Dermatol Surg 2006; 32: 435–41PubMedCrossRefGoogle Scholar
  37. 37.
    Giuffrida T, Kligora CJ, Goldstein GD. Localized cutaneous metastases from an a typical fibroxanthoma. Dermatol Surg 2004; 30: 1561–4PubMedCrossRefGoogle Scholar
  38. 38.
    Jensen K, Peterson SR. Multiple recurrent atypical fibroxanthomas/superficial malignant fibrous histiocytomas of the forehead excised with Mohs micrographic surgery (MMS). Dermatol Surg 2006; 32: 588–91PubMedCrossRefGoogle Scholar
  39. 39.
    Nakai N, Takenaka H, Kishimoto S. A typical fibroxanthoma on a bald scalp. J Dermatol 2005; 32 (10): 848–51PubMedGoogle Scholar
  40. 40.
    Lee D, Grossman ME, Schneiderman P, et al. Genetics of skin appendage neoplasms and related syndromes. J Med Genet 2005; 42: 811–9PubMedCrossRefGoogle Scholar
  41. 41.
    Zhang X, Liang YH, He PP, et al. Identification of the cylindromatosis tumor suppressor gene responsible for multiple familial trichoepithelioma. J Invest Dermatol 2004; 122: 658–64PubMedCrossRefGoogle Scholar
  42. 42.
    Rallan D, Harland CC. Brooke-Spiegler syndrome: treatment with laser ablation. Clin Exp Dermatol 2005 Jul; 30 (4): 355–7PubMedCrossRefGoogle Scholar
  43. 43.
    Santibanez-Gallerani A, Marshall D, Duarte AM, et al. Should nevus sebaceus of Jadassohn in children be excised? A study of 757 cases, and literature review. J Craniofac Surg 2003 Sept; 14 (5): 658–60Google Scholar
  44. 44.
    Bichakjian C, Lowe L, Lao CD, et al. Merkel cell carcinoma: critical review with guidelines for multidisciplinary management. Cancer 2007 Jul; 110 (1): 1–12PubMedCrossRefGoogle Scholar
  45. 45.
    Clark J, Veness MJ, Gilbert R, et al. Merkel cell carcinoma of the head and neck: is adjuvant radiotherapy necessary? Head Neck 2007; 29: 249–57PubMedCrossRefGoogle Scholar
  46. 46.
    Feng H, Shuda M, Chang Y, et al. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008 Feb 22; 319 (5866): 1096–100PubMedCrossRefGoogle Scholar
  47. 47.
    Sihto H, Kukko H, Koljonen V, et al. Clinical factors associated with Merkel cell polyomavirus infection in Merkel cell carcinoma. J Natl Cancer Inst 2009; 101: 938–45PubMedCrossRefGoogle Scholar
  48. 48.
    Gandhi RK, Rosenberg AS, Somach SC. Merkel cell polyomavirus: an update. J Cutan Pathol 2009 Dec; 36 (12): 1327–9PubMedCrossRefGoogle Scholar
  49. 49.
    Stein R, Spencer JM. Painful cutaneous metastases from esophageal carcinoma. Cutis 2002 Oct; 70 (4): 230–2PubMedGoogle Scholar
  50. 50.
    Sabir S, James W, Schuchter L. Cutaneous manifestations of cancer. Curr Opin Oncol 1999 Mar; 11 (2): 139–44PubMedCrossRefGoogle Scholar
  51. 51.
    Cohen P. Skin clues to primary and metastatic malignancy. Am Fam Physician 1995; 51 (5): 1199–204PubMedGoogle Scholar
  52. 52.
    Llancapi P, Gutierrez R, Paiva O. Cutaneous metastases: clinical pathological review. Rev Med Chil 1996 Dec; 124 (12): 1519–23PubMedGoogle Scholar
  53. 53.
    Mueller T, Wu H, Greenberg RE, et al. Cutaneous metastases from genitourinary malignancies. J Urol 2004; 63: 1021–6CrossRefGoogle Scholar
  54. 54.
    Dahl P, Brodland DG, Goellner JR, et al. Thyroid carcinoma metastatic to the skin: a cutaneous manifestation of a widely disseminated malignancy. J Am Acad Dermatol 1997; 36: 531–7PubMedCrossRefGoogle Scholar
  55. 55.
    Roh E, Nord R, Jukic DM. Scalp metastasis from esophageal adenocarcinoma. Cutis 2006 Feb; 77 (2): 106–8PubMedGoogle Scholar
  56. 56.
    Yuen Y, Lewis EJ, Larson JT, et al. Scalp metastases mimicking alopecia areata: first case report of placental site trophoblastic tumor presenting as cutaneous metastasis. Dermatol Surg 1998 May; 24 (5): 587–91PubMedCrossRefGoogle Scholar
  57. 57.
    Rendi M, Dhar AD. Cutaneous metastasis of rectal adenocarcinoma. Dermatol Nurs 2003 Apr; 15 (2): 131–2PubMedGoogle Scholar
  58. 58.
    Boswell J, Davis MDP. Violaceous plaque on the forehead clinically resembling angiosarcoma: cutaneous metastasis in a patient with prostatic adenocarcinoma. J Am Acad Dermatol 2005 Oct; 53 (4): 744–5PubMedCrossRefGoogle Scholar
  59. 59.
    Kushner D, Lurain JR, Fu TS, et al. Endometrial adenocarcinoma metastatic to the scalp: case report and literature review. Gynecol Oncol 1997; 65: 530–3PubMedCrossRefGoogle Scholar
  60. 60.
    Shimizu S, Nagata Y, Han-yaku H. Metastatic testicular choriocarcinoma of the skin: report and review of the literature. Am J Dermatopathol 1996 Dec; 18 (6): 633–6PubMedCrossRefGoogle Scholar
  61. 61.
    Fisher C. Epithelioid sarcoma of Enzinger. Adv Anat Pathol 2006 May; 13 (3): 114–21PubMedCrossRefGoogle Scholar
  62. 62.
    Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768–85PubMedCrossRefGoogle Scholar
  63. 63.
    Bogle M, Riddle CC, Triana EM, et al. Primary cutaneous B-cell lymphoma. J Am Acad Dermatol 2005; 53: 479–84PubMedCrossRefGoogle Scholar
  64. 64.
    Whittaker S. Molecular genetics of cutaneous lymphomas. Ann N Y Acad Sci 2001 Sep; 941: 39–45PubMedCrossRefGoogle Scholar
  65. 65.
    Gilliam A, Lessin SR, Wilson DM, et al. Folliculotropic mycosis fungoides with large-cell transformation presenting as dissecting cellulitis of the scalp. J Cutan Pathol 1997 Mar; 24 (3): 169–75PubMedCrossRefGoogle Scholar
  66. 66.
    Kempf W. CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators. J Clin Pathol 2006; 33 Suppl. 1: 58–70Google Scholar
  67. 67.
    Weiss L, Wood GS, Trela M, et al. Clonal T-cell populations in lymphomatoid papulosis: evidence of a lymphoproliferative origin for a clinically benign disease. N Engl J Med 1986 Aug; 315 (8): 475–9PubMedCrossRefGoogle Scholar
  68. 68.
    Campo E, Chott A, Kinney MC, et al. Update on extranodal lymphomas: conclusions of the workshop held by the EHAP and the SH in Thessaloniki, Greece. Histopathology 2006; 48: 481–504PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Heather M. Richmond
    • 1
    • 2
  • Madeleine Duvic
    • 1
  • Deborah F. MacFarlane
    • 1
  1. 1.Department of DermatologyUniversity of Texas, MD Anderson Cancer CenterHoustonUSA
  2. 2.HoustonUSA

Personalised recommendations